Table 1.
Characteristics of the 426 study patients
| Variables | No. (%)/ Mean±SD |
|---|---|
| Female | 288 (67.6%) |
| Male | 138 (32.3%) |
| JIA ILAR category | |
| Persistent oligoarthritis | 79 (18.5%) |
| Extended oligoarthritis | 61 (14.3%) |
| RF-positive polyarthritis | 71 (16.7%) |
| RF-negative polyarthritis | 75 (17.6%) |
| Systemic | 41 (9.6%) |
| Enthesitis-related arthritis | 80 (18.8%) |
| Psoriatic arthritis | 13 (3.1%) |
| Undifferentiated arthritis | 6 (1.4%) |
| Age at disease onset (years) (n=423) | 9.9±4.8 |
| Age at diagnosis (years) (n=399) | 14.4±9.9 |
| Age at the time of last registered visit (years) | 34.1±12.8 |
| Disease duration (years) (n=423) | 22.5±12.4 |
| ANA+ (n=244) | 75 (30.7%) |
| RF + (n=320) | 88 (27.5%) |
| ACPA + (n=121) | 37 (30.8%) |
| HLA B27 + (n=189) | 75 (30.7%) |
| Years of education (n=234) | 11.6±3.7 |
| Current professional situation (n=234) | |
| Employed | 168 (71.8%) |
| Unemployed | 24 (10.3%) |
| Retired | 11 (4.7%) |
| Retired due to JIA disability | 31 (13.2%) |
| Disease activity (n=300) | |
| Active disease | 201 (67%) |
| Inactive disease | 99 (33%) |
| HAQ Score (n=426) | 0.5±0.7 |
| JADI-A Score (n=140) | 7.7±14.5 |
| JADI-E Score (n=111) | 0.8±1.6 |
| Past treatment | |
| Patients who had received corticosteroids (n=399) | 80 (20%) |
| Patients who had received synthetic DMARDs (n=399) | 84 (21%) |
| Patients who had received biological DMARDs (n=399) | 31 (7.8%) |
| Current treatment | |
| Patients who were on corticosteroids (n=399) | 103 (25.8%) |
| Patients who were on synthetic DMARDs (n=399) | 245 (61.4%) |
| Patients who were on biological DMARDs (n=399) | 140 (35.1%) |
| Cumulative corticosteroid exposure (years) (n=175) | 8.3±8.9 |
| Cumulative synthetic DMARDs exposure (years) (n=326) | 10.6±9.5 |
| Cumulative biological DMARDs exposure (years) (n=173) | 6.1±3.7 |
ACPA, anticitrullinated protein antibodies; ANAs, antinuclear antibodies; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; ILAR, International League of Associations for Rheumatology; JADI-A, Juvenile Arthritis Damage Index—articular; JADI-E, Juvenile Arthritis Damage Index—extra-articular; JIA, juvenile idiopathic arthritis; RF, rheumatoid factor.